Molecular therapies and precision medicine for hepatocellular carcinoma
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Molecular therapies and precision medicine for hepatocellular carcinoma
Authors
Keywords
-
Journal
Nature Reviews Clinical Oncology
Volume 15, Issue 10, Pages 599-616
Publisher
Springer Nature America, Inc
Online
2018-07-30
DOI
10.1038/s41571-018-0073-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients withRAS-mutated Hepatocellular Carcinoma
- (2018) Ho Yeong Lim et al. CLINICAL CANCER RESEARCH
- Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
- (2018) Milind Javle et al. JOURNAL OF CLINICAL ONCOLOGY
- SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma
- (2018) Pierce K.H. Chow et al. JOURNAL OF CLINICAL ONCOLOGY
- The impact of combining Selective Internal Radiation Therapy (SIRT) with Sorafenib on overall survival in patients with advanced hepatocellular carcinoma: The Soramic trial palliative cohort
- (2018) J. Ricke et al. JOURNAL OF HEPATOLOGY
- Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial
- (2018) Richard S. Finn et al. JOURNAL OF HEPATOLOGY
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2018) Peter R. Galle et al. JOURNAL OF HEPATOLOGY
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Targeting the PI3K pathway in cancer: are we making headway?
- (2018) Filip Janku et al. Nature Reviews Clinical Oncology
- Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
- (2018) Dai Fukumura et al. Nature Reviews Clinical Oncology
- Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
- (2018) Kabir A. Khan et al. Nature Reviews Clinical Oncology
- REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib.
- (2018) Andrew X. Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase 3 CELESTIAL trial.
- (2018) Ghassan K. Abou-Alfa et al. JOURNAL OF CLINICAL ONCOLOGY
- Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis
- (2017) Daniela Sia et al. GASTROENTEROLOGY
- Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
- (2017) Daniela Sia et al. GASTROENTEROLOGY
- Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation
- (2017) Jean-Charles Nault et al. GASTROENTEROLOGY
- KEYNOTE-240: Randomized phase III study of pembrolizumab versus best supportive care for second-line advanced hepatocellular carcinoma.
- (2017) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- KEYNOTE-224: Phase II study of pembrolizumab in patients with previously treated advanced hepatocellular carcinoma.
- (2017) Andrew X. Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine
- (2017) Makoto Isono et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Molecular predictors of recurrence prevention with sorafenib as adjuvant therapy in hepatocellular carcinoma: Biomarker study of the STORM phase III trial
- (2017) R. Pinyol et al. JOURNAL OF HEPATOLOGY
- Reply to: “mRECIST for systemic therapies: More evidence is required before recommendations could be made”
- (2017) Robert Montal et al. JOURNAL OF HEPATOLOGY
- Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies
- (2017) Jordi Bruix et al. JOURNAL OF HEPATOLOGY
- Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC
- (2017) Riccardo Lencioni et al. JOURNAL OF HEPATOLOGY
- Trunk mutational events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma
- (2017) Sara Torrecilla et al. JOURNAL OF HEPATOLOGY
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial
- (2017) Valérie Vilgrain et al. LANCET ONCOLOGY
- Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma
- (2017) Rui-hua Xu et al. NATURE MATERIALS
- Integrating liquid biopsies into the management of cancer
- (2017) Giulia Siravegna et al. Nature Reviews Clinical Oncology
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics
- (2017) Dearbhaile C. Collins et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models
- (2016) Iris Martinez-Quetglas et al. GASTROENTEROLOGY
- Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma
- (2016) Kenji Ikeda et al. JOURNAL OF GASTROENTEROLOGY
- Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study
- (2016) Jorge A. Marrero et al. JOURNAL OF HEPATOLOGY
- Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial
- (2016) Riccardo Lencioni et al. JOURNAL OF HEPATOLOGY
- Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study
- (2016) Masatoshi Kudo et al. LIVER INTERNATIONAL
- Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy
- (2016) Hong Jiang et al. NATURE MEDICINE
- Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
- (2016) Celine Boutros et al. Nature Reviews Clinical Oncology
- Reining in the supersized Phase I cancer trial
- (2016) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- Hepatocellular carcinoma
- (2016) Josep M. Llovet et al. Nature Reviews Disease Primers
- Validation of biomarkers to predict response to immunotherapy in cancer: Volume I — pre-analytical and analytical validation
- (2016) Giuseppe V. Masucci et al. Journal for ImmunoTherapy of Cancer
- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- Genetic Landscape and Biomarkers of Hepatocellular Carcinoma
- (2015) Jessica Zucman-Rossi et al. GASTROENTEROLOGY
- DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma
- (2015) Augusto Villanueva et al. HEPATOLOGY
- Toxicities of Immunotherapy for the Practitioner
- (2015) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma
- (2015) Andrew X. Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial
- (2015) Calin Cainap et al. JOURNAL OF CLINICAL ONCOLOGY
- Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study
- (2015) Gottfried E Konecny et al. LANCET ONCOLOGY
- Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
- (2015) Andrew X Zhu et al. LANCET ONCOLOGY
- Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
- (2015) Jordi Bruix et al. LANCET ONCOLOGY
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
- (2015) S. P. Patel et al. MOLECULAR CANCER THERAPEUTICS
- Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
- (2015) Stefani Spranger et al. NATURE
- Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets
- (2015) Kornelius Schulze et al. NATURE GENETICS
- Advances in targeted therapies for hepatocellular carcinoma in the genomic era
- (2015) Josep M. Llovet et al. Nature Reviews Clinical Oncology
- Combination cancer immunotherapies tailored to the tumour microenvironment
- (2015) Mark J. Smyth et al. Nature Reviews Clinical Oncology
- Releasing the Brakes on Cancer Immunotherapy
- (2015) Antoni Ribas NEW ENGLAND JOURNAL OF MEDICINE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway
- (2015) M. Hagel et al. Cancer Discovery
- A Phase II Study of the Efficacy and Safety of the Combination Therapy of the MEK Inhibitor Refametinib (BAY 86-9766) Plus Sorafenib for Asian Patients with Unresectable Hepatocellular Carcinoma
- (2014) H. Y. Lim et al. CLINICAL CANCER RESEARCH
- Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design
- (2014) J. M. Llovet et al. CLINICAL CANCER RESEARCH
- Development of Hong Kong Liver Cancer Staging System With Treatment Stratification for Patients With Hepatocellular Carcinoma
- (2014) Thomas Yau et al. GASTROENTEROLOGY
- Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial
- (2014) Masatoshi Kudo et al. HEPATOLOGY
- Genomic portrait of resectable hepatocellular carcinomas: Implications ofRB1andFGF19aberrations for patient stratification
- (2014) Sung-Min Ahn et al. HEPATOLOGY
- Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
- (2014) Andrew X. Zhu et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib
- (2014) Maria Reig et al. JOURNAL OF HEPATOLOGY
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Trans-ancestry mutational landscape of hepatocellular carcinoma genomes
- (2014) Yasushi Totoki et al. NATURE GENETICS
- Pragmatic issues in biomarker evaluation for targeted therapies in cancer
- (2014) Armand de Gramont et al. Nature Reviews Clinical Oncology
- A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer
- (2013) A. X. Zhu et al. CLINICAL CANCER RESEARCH
- Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET
- (2013) C. Basilico et al. CLINICAL CANCER RESEARCH
- Targeting the HGF/c-MET Pathway in Hepatocellular Carcinoma
- (2013) L. Goyal et al. CLINICAL CANCER RESEARCH
- Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study
- (2013) Jordi Bruix et al. EUROPEAN JOURNAL OF CANCER
- Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma
- (2013) Kai Wang et al. HEPATOLOGY
- Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
- (2013) Philip J. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia
- (2013) Shukui Qin et al. JOURNAL OF CLINICAL ONCOLOGY
- Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study
- (2013) Josep M. Llovet et al. JOURNAL OF CLINICAL ONCOLOGY
- Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
- (2013) Ann-Lii Cheng et al. JOURNAL OF CLINICAL ONCOLOGY
- A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
- (2013) Bruno Sangro et al. JOURNAL OF HEPATOLOGY
- Targeting the mTOR pathway in hepatocellular carcinoma: Current state and future trends
- (2013) Matthias S. Matter et al. JOURNAL OF HEPATOLOGY
- Alpha-fetoprotein: a renaissance
- (2013) A. A. Terentiev et al. TUMOR BIOLOGY
- Erratum: Corrigendum: High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions
- (2013) Jean Charles Nault et al. Nature Communications
- Abstract 3858: Gains in FGF19 are predictive of response to the fibroblast growth factor receptor (FGFR) small molecule tyrosine kinase inhibitor BGJ 398in vitro
- (2012) Richard S. Finn et al. CANCER RESEARCH
- Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma
- (2012) J. M. Llovet et al. CLINICAL CANCER RESEARCH
- Wnt-Pathway Activation in Two Molecular Classes of Hepatocellular Carcinoma and Experimental Modulation by Sorafenib
- (2012) A. Lachenmayer et al. CLINICAL CANCER RESEARCH
- Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
- (2012) Armando Santoro et al. LANCET ONCOLOGY
- FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor
- (2012) V. Guagnano et al. Cancer Discovery
- Identification of a Therapeutic Strategy Targeting Amplified FGF19 in Liver Cancer by Oncogenomic Screening
- (2011) Eric T. Sawey et al. CANCER CELL
- MicroRNA-Based Classification of Hepatocellular Carcinoma and Oncogenic Role of miR-517a
- (2011) Sara Toffanin et al. GASTROENTEROLOGY
- Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy
- (2011) Massimo Iavarone et al. HEPATOLOGY
- Management of hepatocellular carcinoma: An update
- (2011) Jordi Bruix et al. HEPATOLOGY
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
- (2011) F. M. Yakes et al. MOLECULAR CANCER THERAPEUTICS
- Tumor angiogenesis: molecular pathways and therapeutic targets
- (2011) Sara M Weis et al. NATURE MEDICINE
- TNM seventh edition: What's new, what's changed
- (2010) Leslie H Sobin et al. CANCER
- Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
- (2010) Scott M. Wilhelm et al. INTERNATIONAL JOURNAL OF CANCER
- Doxorubicin Plus Sorafenib vs Doxorubicin Alone in Patients With Advanced Hepatocellular Carcinoma
- (2010) Ghassan K. Abou-Alfa et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Angiogenesis and clinicopathologic characteristics in different hepatocellular carcinoma subtypes defined by EpCAM and α-fetoprotein expression status
- (2010) Yun-feng Shan et al. MEDICAL ONCOLOGY
- Molecular Classification and Novel Targets in Hepatocellular Carcinoma: Recent Advancements
- (2010) Yujin Hoshida et al. SEMINARS IN LIVER DISEASE
- Integrative Transcriptome Analysis Reveals Common Molecular Subclasses of Human Hepatocellular Carcinoma
- (2009) Y. Hoshida et al. CANCER RESEARCH
- FGF19-induced Hepatocyte Proliferation Is Mediated through FGFR4 Activation
- (2009) Xinle Wu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Focal Gains of VEGFA and Molecular Classification of Hepatocellular Carcinoma
- (2008) D. Y. Chiang et al. CANCER RESEARCH
- Multi-Kinase Inhibitor E7080 Suppresses Lymph Node and Lung Metastases of Human Mammary Breast Tumor MDA-MB-231 via Inhibition of Vascular Endothelial Growth Factor-Receptor (VEGF-R) 2 and VEGF-R3 Kinase
- (2008) J. Matsui et al. CLINICAL CANCER RESEARCH
- Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma
- (2008) Augusto Villanueva et al. GASTROENTEROLOGY
- Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. JNCI-Journal of the National Cancer Institute
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
- (2008) Scott M. Wilhelm et al. MOLECULAR CANCER THERAPEUTICS
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma
- (2008) Yujin Hoshida et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started